Free Trial

Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis

0.00 (0.00%)
(As of 07/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.27 million shs
Average Volume
1.70 million shs
Market Capitalization
$303.59 million
P/E Ratio
Dividend Yield
Price Target

Adaptimmune Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
126.6% Upside
$2.79 Price Target
Short Interest
2.29% of Shares Sold Short
Dividend Strength
News Sentiment
1.07mentions of Adaptimmune Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$22,814 Sold Last Quarter
Proj. Earnings Growth
From ($0.61) to ($0.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.24 out of 5 stars

Medical Sector

573rd out of 901 stocks

Biological Products, Except Diagnostic Industry

92nd out of 152 stocks

ADAP stock logo

About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

ADAP Stock Price History

ADAP Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Adaptimmune Q1 2024 Earnings Preview
Adaptimmune Therapeutics Plc - ADR
See More Headlines
Receive ADAP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Pharmaceutical Products
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$60.28 million
Book Value
$0.17 per share


Free Float
Market Cap
$303.59 million
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

ADAP Stock Analysis - Frequently Asked Questions

How have ADAP shares performed this year?

Adaptimmune Therapeutics' stock was trading at $0.7930 at the start of the year. Since then, ADAP shares have increased by 55.1% and is now trading at $1.23.
View the best growth stocks for 2024 here

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) released its quarterly earnings data on Wednesday, May, 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02. The biotechnology company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $4.40 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 259.68% and a negative net margin of 890.13%.

What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO?

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did Adaptimmune Therapeutics IPO?

Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Top institutional shareholders of Adaptimmune Therapeutics include Concourse Financial Group Securities Inc.. Insiders that own company stock include Gavin Wood, Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, John Lunger and Elliot Norry.
View institutional ownership trends

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Adaptimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP) and Micron Technology (MU).

This page (NASDAQ:ADAP) was last updated on 7/25/2024 by Staff

From Our Partners